Related Experiment Video
Updated: Jun 6, 2026
Dynamic Multiparameter Platelet Function Assessment Using a Capacitive Biosensor
Published on: May 2, 2025
[New approaches and indications for the analysis of platelet function in cardiology]
1Klinik für Innere Medizin III (Schwerpunkt Kardiologie und Angiologie), Universitätsklinikum Schleswig-Holstein, Campus Kiel, Schittenhelmstr. 12, 24105 Kiel.
Insights
Anti-platelet therapy is crucial for cardiovascular health but carries bleeding risks. Personalized medicine, using pharmacogenomics, can optimize treatment selection for the best benefit-risk ratio.
Area of Science:
- Cardiovascular Medicine
- Pharmacology
- Hematology
Background:
- Platelets are central to cardiovascular events.
- Current anti-platelet therapies like acetylsalicylic acid and ADP-receptor blockers do not fully inhibit platelet activation.
- Alternative activation pathways, such as via the thrombin receptor, remain a concern.
Purpose of the Study:
- To review the role of platelet inhibition in cardiovascular disease.
- To discuss the balance between reducing ischemic events and increasing bleeding risk with potent anti-platelet agents.
- To explore the potential of personalized medicine, including pharmacogenomics, in optimizing anti-platelet therapy.
Main Methods:
- Review of clinical trials and registries on anti-platelet therapy.
- Analysis of mechanisms of platelet activation.
- Discussion of laboratory diagnostics, including functional platelet tests and pharmacogenomic analyses.
Main Results:
- Potent anti-platelet inhibitors reduce ischemic events but increase bleeding risk.
- Individual patient risk assessment for ischemia and bleeding is essential for selecting appropriate therapy.
- Pharmacogenomic analyses alongside functional tests can aid in personalized anti-platelet treatment.
Conclusions:
- Balancing ischemic and bleeding risks is paramount in anti-platelet therapy.
- Personalized medicine approaches, integrating pharmacogenomics, offer a promising strategy for optimizing anti-platelet treatment selection.
Abstract:
Inhibiting platelet function is a key therapeutic principle in cardiology because platelets play a pivotal role in triggering cardiovascular events. In addition to acetylsalicylic acid, a cyclooxygenase inhibitor, ADP-receptor blockers are frequently used for anti-platelet therapy. This therapy does not abolish platelet activation and aggregation. Platelets may still be activated by alternative routes such as the thrombin receptor-mediated pathway. New, more potent inhibitors of platelet function continue to lower the risk of ischaemic events but several trials and clinical registries have also shown that this advantage was frequently offset by an increased risk of bleeding complications. As a consequence, the individual risk of ischaemia and bleeding of a patient must be taken into consideration to select the platelet inhibitor offering the best benefit-risk ratio. Modern laboratory diagnostics may help to achieve this goal by complementing functional platelet tests with pharmacogenomic analyses consistent with the idea of "personalized medicine".
Related Concept Videos
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:18Structure and Function of Platelets
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000 platelets, with...